NCT00390910View on ClinicalTrials.gov

Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

October 1, 2006

Primary Completion Date

July 2, 2007

Study Completion Date

May 2, 2008

Conditions
Infections, Streptococcal
Interventions
BIOLOGICAL

Pneumococcal conjugate vaccine GSK1024850A

Intramuscular injection, 3 doses

BIOLOGICAL

Infanrix hexa

Intramuscular injection, 3 doses

Trial Locations (8)

11527

GSK Investigational Site, Athens

26500

GSK Investigational Site, Rio/Patras

28047

GSK Investigational Site, Madrid

28935

GSK Investigational Site, Móstoles/Madrid

54636

GSK Investigational Site, Thessaloniki

115 27

GSK Investigational Site, Athens

452 21

GSK Investigational Site, Ioannina

09005

GSK Investigational Site, Burgos

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00390910 - Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants | Biotech Hunter | Biotech Hunter